265 related articles for article (PubMed ID: 16135026)
1. Retrospective analysis of sequential dose-finding designs.
O'Quigley J
Biometrics; 2005 Sep; 61(3):749-56. PubMed ID: 16135026
[TBL] [Abstract][Full Text] [Related]
2. Retrospective robustness of the continual reassessment method.
O'Quigley J; Zohar S
J Biopharm Stat; 2010 Sep; 20(5):1013-25. PubMed ID: 20721788
[TBL] [Abstract][Full Text] [Related]
3. Three-dose-cohort designs in cancer phase I trials.
Huang B; Chappell R
Stat Med; 2008 May; 27(12):2070-93. PubMed ID: 17764082
[TBL] [Abstract][Full Text] [Related]
4. Sensitivity of dose-finding studies to observation errors.
Zohar S; O'Quigley J
Contemp Clin Trials; 2009 Nov; 30(6):523-30. PubMed ID: 19580886
[TBL] [Abstract][Full Text] [Related]
5. Dose-escalation designs in oncology: ADEPT and the CRM.
Shu J; O'Quigley J
Stat Med; 2008 Nov; 27(26):5345-53; discussion 5354-5. PubMed ID: 18752259
[TBL] [Abstract][Full Text] [Related]
6. Sequential designs for logistic phase I clinical trials.
Liu G; Rosenberger WF; Haines LM
J Biopharm Stat; 2006; 16(5):605-21. PubMed ID: 17037261
[TBL] [Abstract][Full Text] [Related]
7. Improved designs for dose escalation studies using pharmacokinetic measurements.
Piantadosi S; Liu G
Stat Med; 1996 Aug; 15(15):1605-18. PubMed ID: 8858785
[TBL] [Abstract][Full Text] [Related]
8. A comparison of model choices for the Continual Reassessment Method in phase I cancer trials.
Paoletti X; Kramar A
Stat Med; 2009 Oct; 28(24):3012-28. PubMed ID: 19672839
[TBL] [Abstract][Full Text] [Related]
9. [Continual reassessment method (CRM)].
Ishizuka N
Gan To Kagaku Ryoho; 2000 Aug; 27(9):1449-57. PubMed ID: 10969605
[TBL] [Abstract][Full Text] [Related]
10. Optimal phase I dose-escalation trial designs in oncology--a simulation study.
Gerke O; Siedentop H
Stat Med; 2008 Nov; 27(26):5329-44. PubMed ID: 17849502
[TBL] [Abstract][Full Text] [Related]
11. Dose-finding in phase I clinical trials based on toxicity probability intervals.
Ji Y; Li Y; Nebiyou Bekele B
Clin Trials; 2007; 4(3):235-44. PubMed ID: 17715248
[TBL] [Abstract][Full Text] [Related]
12. Dose-finding designs in pediatric phase I clinical trials: comparison by simulations in a realistic timeline framework.
Doussau A; Asselain B; Le Deley MC; Geoerger B; Doz F; Vassal G; Paoletti X
Contemp Clin Trials; 2012 Jul; 33(4):657-65. PubMed ID: 22521954
[TBL] [Abstract][Full Text] [Related]
13. Designs for phase I clinical trials with multiple courses of subjects at different doses.
Fan SK; Wang YG
Biometrics; 2007 Sep; 63(3):856-64. PubMed ID: 17403103
[TBL] [Abstract][Full Text] [Related]
14. An adaptive dose-finding design incorporating both toxicity and efficacy.
Zhang W; Sargent DJ; Mandrekar S
Stat Med; 2006 Jul; 25(14):2365-83. PubMed ID: 16220478
[TBL] [Abstract][Full Text] [Related]
15. Designing dose-escalation trials with late-onset toxicities using the time-to-event continual reassessment method.
Normolle D; Lawrence T
J Clin Oncol; 2006 Sep; 24(27):4426-33. PubMed ID: 16983110
[TBL] [Abstract][Full Text] [Related]
16. Application of the continual reassessment method to a phase I dose-finding trial in Japanese patients: East meets West.
Morita S
Stat Med; 2011 Jul; 30(17):2090-7. PubMed ID: 21500239
[TBL] [Abstract][Full Text] [Related]
17. An approach to meta-analysis of dose-finding studies.
Zohar S; Katsahian S; O'Quigley J
Stat Med; 2011 Jul; 30(17):2109-16. PubMed ID: 21344473
[TBL] [Abstract][Full Text] [Related]
18. Toxicity equivalence range design (TEQR): a practical Phase I design.
Blanchard MS; Longmate JA
Contemp Clin Trials; 2011 Jan; 32(1):114-21. PubMed ID: 20923709
[TBL] [Abstract][Full Text] [Related]
19. np1: a computer program for dose escalation strategies in phase I clinical trials.
Kramar A; Houédé N; Paoletti X
Comput Methods Programs Biomed; 2007 Oct; 88(1):8-17. PubMed ID: 17719124
[TBL] [Abstract][Full Text] [Related]
20. Adaptive designs for dose-finding in non-cancer phase II trials: influence of early unexpected outcomes.
Resche-Rigon M; Zohar S; Chevret S
Clin Trials; 2008; 5(6):595-606. PubMed ID: 19029208
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
